GH secretagogues: Ipamorelin, CJC-1295, Tesamorelin, GHRP-2, GHRP-6, and Sermorelin: are among the most popular peptide categories in athletics. They raise growth hormone and IGF-1 without exogenous GH, and they are frequently described as "safe with no blood work needed."
That description is almost right, but not entirely. While secretagogues do not stress your liver, kidneys, or cardiovascular system the way AAS or even GH can, there are subtle changes in your blood work that tell you two important things: whether your protocol is actually working, and whether it is still safe to continue.
The reason IGF-1 is your primary readout is that it smooths out the natural pulse pattern of GH. A single GH draw is nearly useless because levels spike and crash within minutes. IGF-1, by contrast, has a half-life of about 12 hours and reflects cumulative GH exposure over the previous 3 to 4 days. That makes it the only practical way to judge whether your secretagogue is actually doing anything. If you are using a weak compound like Sermorelin at 300 mcg once daily, expect a modest 10 to 20% IGF-1 bump. If you are on CJC-1295 with DAC plus GHRP-2 twice daily, a 50% increase is realistic. The key is to establish your personal baseline before starting, then compare at the same lab and same assay. Different labs use different reference ranges, so switching labs mid-cycle will confuse your interpretation.
IGF-1: The Primary Efficacy Marker
If you are using a GH secretagogue, the single most important blood marker is IGF-1. GH secretion is pulsatile and difficult to capture with a single blood draw: but IGF-1 reflects integrated GH output over the preceding days and is much more stable. It is your primary tool for answering the question everyone should ask: is this protocol actually doing anything?
IGF-1 (Insulin-Like Growth Factor 1)
Timing matters. Blood draw timing for IGF-1 is less strict than for GH itself (IGF-1 is stable throughout the day), but you should still draw at the same time of day and in the same fasted state for consistent comparisons. Draw at least 8-12 hours after your last secretagogue dose to capture the integrated effect rather than a post-dose spike.
One common mistake is drawing blood too soon after a dose. Even though IGF-1 is stable, the acute GH spike from a secretagogue can transiently suppress your next endogenous pulse, which may slightly lower IGF-1 if you draw within 4 hours of dosing. Wait at least 8 to 12 hours after your last injection, and ideally draw in the morning after an overnight fast. Also, keep your hydration status consistent. Dehydration can falsely elevate IGF-1 by up to 10% due to hemoconcentration. If you train heavy the day before, that can also blunt GH response and lower IGF-1. So for the 4 week check, replicate your normal routine: same time, same fasted state, same training schedule. If you are on a daily dosing protocol, do not skip your dose the night before the draw, because that would measure a trough, not your average exposure.
Target ranges. A well-functioning secretagogue protocol typically raises IGF-1 by 20-50% from baseline, putting most users in the 250-400 ng/mL range depending on age. If your IGF-1 does not budge after 4 weeks, your dose is too low, your compound is under-dosed, or the secretagogue you are using does not work well for your physiology.
GH Secretagogue Comparison
Not all secretagogues are created equal. Some are more effective at raising IGF-1, some have longer duration, and some introduce additional considerations:
The differences between secretagogues matter for blood work. GHRP-6 is the worst offender for prolactin because it strongly activates the ghrelin receptor, which stimulates lactotrophs. At 100 mcg per dose, prolactin can rise 20 to 30% above baseline in some users, though it rarely goes out of the normal range. GHRP-2 is milder, and Ipamorelin has almost no prolactin effect. CJC-1295 with DAC, because it keeps GH elevated for days, can push IGF-1 higher than any other secretagogue, but it also carries a higher risk of glucose dysregulation. Tesamorelin is unique: it is a GHRH analog that does not stimulate prolactin at all, and it has been shown to reduce visceral fat, but it can cause a mild increase in cortisol in some users. If you are stacking multiple secretagogues, the prolactin and glucose effects are additive, so your monitoring should reflect the total load.
GH Secretagogues Compared
| Marker | Ipamorelin | CJC-1295 (with DAC) |
|---|---|---|
| Mechanism | GHRP agonist — pure GH pulse | GHRH analog — sustained GH release |
| Duration of Action | ~2 hours per dose | ~7-14 days per dose (with DAC) |
| IGF-1 Increase | Modest (20-40%), dose-dependent | Significant (40-80%), sustained |
| Prolactin Effect | Minimal | None (GHRH, not ghrelin receptor) |
GHRP-6 vs. Sermorelin
| Marker | GHRP-6 | Sermorelin |
|---|---|---|
| Mechanism | GHRP agonist — ghrelin receptor | GHRH analog — pituitary stimulation |
| IGF-1 Increase | Moderate (30-60%) | Modest (15-30%) |
| Prolactin Effect | Significant — ghrelin cross-talk raises prolactin | None — no prolactin elevation |
| Cortisol Effect | Mild ACTH stimulation possible | None |
| Appetite Effect | Strong hunger increase (ghrelin agonist) | None |
Prolactin
Cortisol: The Subtle Signal
Ghrelin receptor agonists (GHRP-2, GHRP-6) can stimulate ACTH release, which in turn raises cortisol. The effect is subtle in most users but measurable in some, particularly at higher doses or with longer protocols. Cortisol elevation is typically not clinically significant at moderate secretagogue doses, but if you are combining secretagogues with other stressors (heavy training, calorie restriction, sleep deprivation), the cumulative cortisol load can affect recovery, body composition, and immune function.
Morning cortisol is the easiest marker to track. If you notice changes in sleep quality, water retention, or recovery that coincide with your secretagogue use, cortisol is worth a look: though most users will never see a meaningful change in this marker.
If you do decide to check cortisol, draw it within 30 minutes of waking, before any food or caffeine. A morning cortisol above 25 mcg/dL is a red flag, but transient elevations from secretagogues are usually mild, staying in the 18 to 22 range. The bigger issue is chronic elevation, which can suppress thyroid function and reduce testosterone. If your cortisol comes back high, do not panic. First, rule out stress, poor sleep, or overtraining. Then consider reducing your GHRP dose or switching to a GHRH-only compound like Sermorelin. In practice, a clinically meaningful cortisol change from secretagogue use alone is uncommon. If you are one of them, you will notice it in your sleep quality and water retention before the blood test confirms it. A single high reading is not diagnostic; repeat it after a week of normal sleep and training.
Glucose Impact on Secretagogues
Secretagogues raise GH, and GH raises glucose. However, the effect is much smaller than with exogenous GH because the total GH output from secretagogues is typically lower. Most users will not see significant changes in fasting glucose or HbA1c from secretagogues alone.
The exception: long-term users (6+ months of continuous use), high-dose protocols (multiple daily doses of potent secretagogues like CJC-1295 with DAC + GHRP-6), and users with pre-existing insulin sensitivity concerns. For these groups, an annual HbA1c check is sensible.
For the high-risk groups, glucose monitoring should be proactive, not reactive. If you are on CJC-1295 with DAC plus GHRP-6 for more than 6 months, check fasting glucose every 8 weeks and HbA1c every 6 months. A fasting glucose creeping from 85 to 95 mg/dL is your early warning. Berberine (commonly 500 mg twice daily with meals) is a reasonable first step you can start yourself; metformin is a prescription medication, so that's a licensed medical professional's call, not a self-start. Most users see glucose return toward baseline within 4 weeks of addressing it. Do not wait for HbA1c to cross 5.7%. Also, be aware that secretagogues raise glucose mainly through GH's effect on hepatic gluconeogenesis, not through insulin resistance. So your fasting insulin may stay normal even as glucose rises. If you are already insulin resistant, consider using Ipamorelin instead of GHRP-6, because it has a weaker effect on glucose. And always time your doses away from high-carb meals to blunt the postprandial spike.
CJC-1295 with DAC: A Special Case
Practical Monitoring Schedule
For most secretagogue users, the monitoring burden is low but not zero. Here is the minimal practical protocol:
A practical mistake many athletes make is skipping the baseline panel. You cannot interpret a 4 week IGF-1 result without knowing your starting point. Also, do not use the same reference range for everyone. A 25 year old with an IGF-1 of 300 ng/mL is already at the top of the range, so a 20% increase would put them at 360, which is fine. But a 45 year old with a baseline of 150 ng/mL needs to reach at least 200 to see any anabolic effect. If your IGF-1 does not move after 4 weeks, check your peptide quality. Many underground lab products are underdosed or degraded. Switch to a different source and retest after 2 weeks. Also, verify your injection technique: subcutaneous injections into belly fat work best for these peptides. Intramuscular injections can cause faster clearance and lower IGF-1 response. Finally, do not chase a higher number by doubling your dose. More is not better; it just increases prolactin and glucose side effects.
- Baseline: IGF-1, prolactin, morning cortisol, fasting glucose, HbA1c
- Week 4: IGF-1 only: to confirm the protocol is working. Also check prolactin if using GHRP-6
- Week 12: Full repeat of baseline panel, especially IGF-1 and glucose markers
- Annually for long-term users: HbA1c, fasting glucose, and consider an OGTT if using potent secretagogues
Secretagogues do not affect liver enzymes (AST, ALT, GGT), kidney markers (creatinine, eGFR), or lipid panels (HDL, LDL, triglycerides) at moderate doses. If you see changes in these markers, the cause is likely something else in your stack: not the secretagogue.